Skip to content
Screener

BridgeBio Pharma BBIO Q2 2025 earnings

Reported August 5, 2025 · After market close

Revenue$110.6MBeat by $2.4M
EPS-$0.95Miss by $0.12
Revenue estimate$108.1M
EPS estimate-$0.83

Next report

Oct 28, 2026 (in 2 months)
Revenue estimate$267.3M
EPS estimate-$0.67

Financials

Q2 2025

Income statement

See full
Revenue$110.6M+5,000%
Gross profit$106.9M+6,710%
Operating income-$134.3M+23.5%
Net income-$183.8M-143%
EPS (diluted)-$0.95-144%

Balance sheet

See full
Cash & equivalents$751.1M+84.1%
Total debt$8.8M-98.0%
Total equity-$1.8B-63.6%
Total assets$1.1B+36.0%

Cash flow

See full
Operating cash flow-$80.7M—
CapEx$594.0K+1,000%
Free cash flow-$81.3M—

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$8.44B+78.1%
Enterprise value$7.7B+61.1%
P/S35.8×+14.2×

Profitability

See full
Gross margin96.2%-2.7pp
Operating margin-278.4%+67.6pp
Net margin-332.9%+461pp
FCF margin-278.4%—

Returns & leverage

See full
Current ratio5.2×+0.6×

FAQ

When did BridgeBio Pharma report Q2 2025 earnings?
BridgeBio Pharma (BBIO) reported Q2 2025 earnings on August 5, 2025 after market close.
What were BridgeBio Pharma's Q2 2025 revenue and EPS?
BridgeBio Pharma reported revenue of $110.6M and eps of $-0.95 for Q2 2025.
Did BridgeBio Pharma beat estimates in Q2 2025?
Revenue beat the consensus estimate of $108.1M by $2.4M. EPS missed the consensus estimate of $-0.83 by $0.12.
How did BridgeBio Pharma's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 4999.9% from $2.2M a year earlier and eps grew 6.9% from $-1.02.
Where can I find BridgeBio Pharma's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-102985) and the 10-Q periodic report (0000950170-25-103192) directly on SEC EDGAR. The filing index links above go to sec.gov.